Histological Outcome of Fuzheng Huayu plus Entecavir Combination Therapy in Chronic Hepatitis B Patients with Significant Liver Fibrosis
Honglian Gui, Changqing Zhao, Yan Wang, Hong-Tu Gu, Weijing Wang, Wei Cai, Qing Guo, Shisan Bao, Lieming Xu, Qing Xie
Abstract
The combination therapy of FZHY plus ETV for 48 weeks resulted in a higher rate of necroinflammatory improvement and fibrosis regression than ETV alone in chronic hepatitis B patients with significant fibrosis/cirrhosis. The clinical trial number is ChiCTR-TRC-11001377.
Topics & Concepts
MedicineEntecavirGastroenterologyCirrhosisInternal medicineFibrosisLiver biopsyCombination therapyPlaceboBiopsyChronic hepatitisPathologyImmunologyLamivudineVirusAlternative medicineHepatitis B Virus StudiesLiver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection